CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

被引：0
|
作者：
Masini, C. [1 ]
Vitale, M. G. [1 ]
Maruzzo, M. [2 ]
Procopio, G. [3 ]
De Giorgi, U. [4 ]
Buti, S. [5 ]
Rossetti, S. [6 ]
Iacovelli, R. [7 ]
Guida, A. [8 ]
Atzori, F. [9 ]
Mucciarini, C. [10 ]
Cosmai, L. [11 ]
Vignani, F. [12 ]
Prati, G. [13 ]
Scagliarini, S. [14 ]
Berselli, A. [1 ]
Pinto, C. [1 ]
机构：
[1] Asmn Irccs Reggio Emilia, Struttura Complessa Oncol, Reggio Emilia, Italy
[2] Ist Oncol Veneto, Oncol Med 1, Padua, Italy
[3] Ist Nazl Tumori Milano, Oncol Med, Milan, Italy
[4] Ist Sci Romagnolo Studio F Tumori IRST STL IRCCS, Oncol Med, Meldola, Italy
[5] Azienda Osped Univ Parma, Oncol Med, Parma, Italy
[6] Ist Nazl Tumori Napoli, Oncol Med, Naples, Italy
[7] Azienda Osped Univ Integrata Verona, Oncol Med, Verona, Italy
[8] Inst Gustave Roussy, Parigi, Italy
[9] Azienda Osped Univ Cagliari, Oncol Med, Cagliari, Italy
[10] Osped Ramazzini Carpi, Oncol Med, Carpi, Italy
[11] Ist Ospitalieri Cremona, Nefrol, Cremona, Italy
[12] AO Ordine Mauriziano Torino, Oncol Med, Turin, Italy
[13] Osped Guastalla, Day Hosp Oncol, Guastalla, Italy
[14] Osped Antonio Cardarelli Napoli, Oncol Med, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B1
引用
收藏
页码：17 / 17
页数：1
相关论文
共 50 条
  • [1] CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
    Masini, C.
    Vitale, M. G.
    Maruzzo, M.
    Procopio, G.
    De Giorgi, U.
    Buti, S.
    Rossetti, S.
    Iacovelli, R.
    Guida, A.
    Atzori, F.
    Mucciarini, C.
    Scagliarini, S.
    Vignani, F.
    Prati, G.
    Cosmai, L.
    Berselli, A.
    Pinto, C.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [2] Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study
    Masini, Cristina
    Vitale, Maria Giuseppa
    Maruzzo, Marco
    Procopio, Giuseppe
    de Giorgi, Ugo
    Buti, Sebastiano
    Rossetti, Sabrina
    Iacovelli, Roberto
    Atzori, Francesco
    Cosmai, Laura
    Vignani, Francesca
    Prati, Giuseppe
    Scagliarini, Sarah
    Guida, Annalisa
    Berselli, Annalisa
    Pinto, Carmine
    [J]. CLINICAL GENITOURINARY CANCER, 2019, 17 (01) : E150 - E155
  • [3] The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-UR0-01 study.
    Vitale, Maria Giuseppa
    Masini, Cristina
    Procopio, Giuseppe
    De Giorgi, Ugo
    Buti, Sebastiano
    Rossetti, Sabrina
    Iacovelli, Roberto
    Mucciarini, Claudia
    Cosmai, Laura
    Vignani, Francesca
    Prati, Giuseppe
    Scagliarini, Sarah
    Berselli, Annalisa
    Pinto, Carmine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC).
    Gore, M. E.
    Jones, R. J.
    Ravaud, A.
    Kuczyk, M.
    Demkow, T.
    Bearz, A.
    Laferriere, N.
    Strauss, U. P.
    Porta, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Wells, J. Connor
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Knox, Jennifer J.
    Beuselinck, Benoit
    Vaishampayan, Ulka N.
    Brugarolas, James
    Broom, Reuben James
    Bamias, Aristotelis
    Yuasa, Takeshi
    Srinivas, Sandhya
    Ernst, D. Scott
    Pezaro, Carmel Jo
    Wood, Lori
    Kollmannsberger, Christian K.
    Rini, Brian I.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Swierkowski, Marcin
    Wells, Connor
    Fraccon, Anna Paola
    La Russa, Francesca
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Sim, Hao-Wen
    Beuselinck, Benoit
    Wood, Lori
    Yuasa, Takeshi
    Pezaro, Carmel Jo
    Rini, Brian I.
    Szczylik, Cezary
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Gupta, Shiva
    Kang, Hyunseon C.
    Sun, Jia
    Matrana, Marc R.
    Tannir, Nizar M.
    Choi, Haesun
    [J]. ABDOMINAL RADIOLOGY, 2020, 45 (06) : 1872 - 1882
  • [8] Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Shiva Gupta
    Hyunseon C. Kang
    Jia Sun
    Marc R. Matrana
    Nizar M. Tannir
    Haesun Choi
    [J]. Abdominal Radiology, 2020, 45 : 1872 - 1882
  • [9] Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC)
    Jonasch, E.
    Bair, A.
    Chen, Y.
    Rini, B. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
    Paolo Grassi
    Elena Verzoni
    Raffaele Ratta
    Luca Porcu
    Michele Prisciandaro
    Alessia Mennitto
    Giuseppina Calareso
    Filippo de Braud
    Giuseppe Procopio
    [J]. Drugs in R&D, 2017, 17 : 461 - 467
12345